Get the Stockscreener App
297.02
2.48%
-7.56
Pre-market:
297.00
-0.02
-0.01%
Praxis Precision Medicines Inc stock is traded at $297.02, with a volume of 684.34K.
It is down -2.48% in the last 24 hours and up +51.19% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$304.58
Open:
$304
24h Volume:
684.34K
Relative Volume:
0.68
Market Cap:
$7.43B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-32.39
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+7.72%
1M Performance:
+51.19%
6M Performance:
+590.74%
1Y Performance:
+289.48%
1-Day Range:
$285.95
$305.49
1-Week Range:
$266.51
$317.72
52-Week Range:
$26.70
$317.72
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
297.02 | 7.62B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug - ts2.tech
Praxis Precision Medicines stock gets FDA boost as H.C. Wainwright maintains Buy - Investing.com Canada
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.4%Here's Why - MarketBeat
Praxis Precision (PRAX) Shares Drop Amid Market Movement - GuruFocus
Truist Securities reiterates Buy rating on Praxis Precision Medicines stock - Investing.com India
Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide - Yahoo Finance
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target - ts2.tech
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
Praxis Precision Medicines Stock Pre-Market (+12%) : FDA Breakthrough Therapy Designation for Ulixacaltamide - Trefis
Praxis Precision Medicines Stock Surges: What Drives the Wave? - StocksToTrade
Why Praxis Precision Medicines Stock Popped Today - Finviz
Why Praxis Precision Medicines Stock Popped Today - The Motley Fool
Praxis Precision Medicines: An Unexpected Surge? - timothysykes.com
Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More Movers - Barron's
Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock jumps after FDA grants breakthrough therapy designation By Investing.com - Investing.com South Africa
Praxis Precision Medicines Soars on FDA Breakthrough Therapy Designation - GuruFocus
Why Is Praxis Precision Medicines Stock Soaring Monday?Praxis Precision Medicine (NASDAQ:PRAX) - Benzinga
Praxis Precision (PRAX) Soars 14.7% on Market Uptick - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month HighTime to Buy? - MarketBeat
Praxis Precision Medicines stock jumps after FDA grants breakthrough therapy designation - Investing.com
Praxis Precision Medicines (PRAX) Surges on FDA Breakthrough Des - GuruFocus
Jefferies reiterates Buy rating on Praxis Precision Medicines stock, cites FDA breakthrough designation - Investing.com UK
Why did Praxis Precision stock surge 12% pre-market today? - MSN
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
PRAX Stock Gains as FDA Grants Breakthrough Therapy Status to Ul - GuruFocus
Why Did Praxis Precision Stock Surge 12% Pre-Market Today? - Asianet Newsable
Praxis Precision Medicines stock soars after FDA grants Breakthrough status - Investing.com
Praxis Precision Medicines stock soars after FDA grants Breakthrough status By Investing.com - Investing.com South Africa
Praxis Precision Medicines receives FDA breakthrough designation for ulixacaltamide By Investing.com - Investing.com Nigeria
Praxis Precision Medicines receives FDA breakthrough designation for ulixacaltamide - Investing.com
PRAX Stock Rises 13% in Premarket Trading - GuruFocus
PRAX Receives FDA Breakthrough Therapy Designation for Ulixacalt - GuruFocus
Praxis Wins FDA Breakthrough Status for Ulixacaltamide - TipRanks
Praxis Precision Medicines Receives Breakthrough Therapy Designation from FDA for Ulixacaltamide in Essential Tremor Treatment - Quiver Quantitative
Praxis Precision Medicines Receives Breakthrough Therapy Designation - TradingView — Track All Markets
FDA fast-tracks potential new treatment for people with essential tremor - Stock Titan
Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG - Investing.com
BTIG Raises Price Target for PRAX to $843, Maintains Buy Rating - GuruFocus
Nvidia, Tesla, DigitalBridge, Newmont, Praxis Precision, Ultragenyx, and More Movers - Barron's
Praxis Precision Medicines Earnings Notes - Trefis
FDA-Endorsed Elsunersen Trial Redesign Could Be A Game Changer For Praxis Precision Medicines (PRAX) - Sahm
Congress Asset Management Co. Makes New Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) price target increased by 38.02% to 410.52 - MSN
Praxis Precision Medicines stock hits 52-week high at 283.04 USD - Investing.com Nigeria
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 52-Week HighWhat's Next? - MarketBeat
Medical Stocks To Follow NowDecember 5th - MarketBeat
Aug Wrap: Why Praxis Precision Medicines Inc. stock could be next big winnerMarket Risk Analysis & Fast Entry High Yield Tips - Улправда
Praxis Precision Medicines (PRAX) Price Target Increased by 38.02% to 410.52 - Nasdaq
Assenagon Asset Management S.A. Has $21.72 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.23%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):